Advances in the selection and timing of postoperative radioiodine treatment in patients with differentiated thyroid carcinoma

X Dai, X Ren, J Zhang, Y Zheng, Z Wang… - Annals of Nuclear …, 2024 - Springer
Differentiated thyroid cancer (DTC) is the most common endocrine malignancy. Patients who
receive systematic care typically have a better prognosis. RAI treatment plays a key role in …

Present and future of target therapies and theranostics: refining traditions and exploring new frontiers—highlights from annals of Nuclear Medicine 2021

C Pini, F Gelardi, M Sollini - European Journal of Nuclear Medicine and …, 2022 - Springer
The first clinical application of nuclear medicine treatments can be dated back to 1936, when
John H. Lawrence utilised an artificial radionuclide—phosphorus-32—to treat a case of …

Delay of initial radioactive iodine therapy beyond 3 months has no effect on clinical responses and overall survival in patients with thyroid carcinoma: A cohort study …

F Cheng, J Xiao, F Huang, C Shao, S Ding… - Cancer …, 2022 - Wiley Online Library
Background More than a third of thyroid carcinoma (TC) patients require treatment with
radioactive iodine (RAI), but the timing of initial RAI therapy after thyroidectomy remains …

[HTML][HTML] Factors affecting ablation success after I-131 radioactive iodine therapy in low and intermediate risk papillary thyroid cancer

S Goksel, U Avci - Hormone and Metabolic Research, 2023 - thieme-connect.com
The study was to evaluate the effect of radioactive iodine (RAI) treatment application time
and clinical, histopathological factors on ablation success in patients with operated papillary …

Impact factors of benefiting from initial 131I ablation in patients with intermediate-risk differentiated thyroid carcinoma: a study based on a re-evaluation of therapeutic …

L Ren, Y Hu, Y Hu, D Xiao, J Sun, B Zhu… - Nuclear Medicine …, 2024 - journals.lww.com
Objective This study was carried out to confirm whether patients with intermediate-risk
differentiated thyroid cancer (DTC) could benefit from initial 131 I ablation and to identify the …

Analysis of delayed initial radioactive iodine therapy and clinical outcomes in papillary thyroid cancer: a two-center retrospective study

T He, M Li, Z Gao, X Li, H Zhong, C Ding… - Nuclear Medicine …, 2024 - journals.lww.com
Background It remains unclear whether the time interval between total thyroidectomy and
radioactive iodine (RAI) therapy influences clinical outcomes in papillary thyroid carcinoma …

[HTML][HTML] Effect of Hashimoto's Thyroiditis on Efficacy of 131I Ablation Therapy in Intermediate-and High-Risk of Thyroid Papillary Carcinoma

L Zhou, G Cheng - Journal of Biosciences and Medicines, 2023 - scirp.org
Objective: The purpose of this study was to investigate the effect of Hashimoto's thyroiditis on
efficacy of 131I ablation in intermediate-and high-risk of thyroid papillary carcinoma patients …

Administración de Yodoterapia temprana vs. tardía en pacientes con cáncer diferenciado de tiroides: revisión sistemática y meta-análisis

LS Mora Alcoser - 2021 - repositorio.uisek.edu.ec
El cáncer de tiroides (CT) es la patología maligna más frecuente del sistema endocrino. El
tipo de CT más común es el cáncer diferenciado de tiroides (CDT) que agrupa al cáncer …

[引用][C] Radioactive iodine timing in differentiated thyroid carcinoma: A meta-analysis

IA Albalawi, HO Mirghani - Teikyo …, 2021 - Teikyo University School of Medicine